You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 596 Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
596 Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to March 2024

AbstractFullPdf
Nov 2021369020
Dec 20219608
Jan 202290010
Feb 20226005
Mar 202215408
Apr 20227208
May 202236014
Jun 20221204
Jul 2022800
Aug 20221402
Sep 20221607
Oct 20221604
Nov 20221804
Dec 20221002
Jan 2023803
Feb 20231406
Mar 20231601
Apr 2023604
May 2023605
Jun 2023601
Jul 20231809
Aug 2023801
Sep 2023800
Oct 20231003
Nov 20232002
Dec 20234805
Jan 20242001
Feb 2024602
Mar 20241806
Total11830145